| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GSY; GYS; GYS1 |
| Entrez GeneID | 2997 |
| clone | 3A7 |
| WB Predicted band size | 85kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GYS1 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于GYS1抗体的模拟参考文献示例(非真实文献，仅供参考格式)：
1. **《GYS1 Antibody Reveals Altered Glycogen Synthesis in Hepatocellular Carcinoma》**
*作者：Zhang L, et al. (2021)*
**摘要**：本研究利用GYS1特异性抗体，发现肝癌细胞中GYS1蛋白表达显著上调，提示糖原合成异常可能通过调控Wnt/β-catenin通路促进肿瘤代谢重编程。
2. **《Targeting GYS1 with Monoclonal Antibodies Inhibits Skeletal Muscle Glycogen Storage in Type 2 Diabetes》**
*作者：Smith J, et al. (2020)*
**摘要**：通过开发高亲和力GYS1抗体，证实抑制GYS1活性可减少骨骼肌糖原过度积累，改善糖尿病模型小鼠的胰岛素抵抗，为代谢疾病治疗提供新靶点。
3. **《A Novel GYS1-Specific Antibody for Detecting Glycogen Synthase 1 in Cardiac Hypertrophy Models》**
*作者：Wang Y, et al. (2022)*
**摘要**：该研究报道了一种新型GYS1抗体的开发及应用，发现心肌肥厚过程中GYS1表达与氧化应激相关，提示其可能参与心脏能量代谢失衡机制。
4. **《GYS1 Antibody-Based Screening Identifies Metabolic Vulnerabilities in Triple-Negative Breast Cancer》**
*作者：Chen R, et al. (2023)*
**摘要**：利用GYS1抗体筛选三阴性乳腺癌细胞系，揭示GYS1高表达与糖原依赖的肿瘤细胞存活相关，靶向GYS1可增强化疗敏感性。
---
**提示**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词“GYS1 antibody”、“glycogen synthase 1”等获取。
The GYS1 antibody is a crucial tool for studying glycogen synthase 1 (GYS1), a rate-limiting enzyme encoded by the *GYS1* gene that catalyzes glycogen synthesis by forming α-1.4-glycosidic linkages in glucose polymers. GYS1 is predominantly expressed in skeletal muscle and other tissues, while its isoform, GYS2. is liver-specific. Dysregulation of GYS1 is linked to metabolic disorders and cancer. Mutations in *GYS1* are associated with glycogen storage disease type 0 (GSD0), characterized by hypoglycemia and muscle weakness. In cancer, GYS1 overexpression has been observed in hepatocellular carcinoma, breast cancer, and gliomas, where aberrant glycogen metabolism supports tumor proliferation and survival under hypoxic or nutrient-deprived conditions.
GYS1 antibodies enable the detection and quantification of GYS1 protein levels in research applications such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help investigate GYS1's role in metabolic reprogramming, a hallmark of cancer, and its interplay with signaling pathways like AKT/mTOR. Commercial GYS1 antibodies are typically raised in rabbits or mice, with validation in specific experimental models. Recent studies also explore GYS1 inhibition as a therapeutic strategy to disrupt cancer cell energy metabolism. However, cross-reactivity with GYS2 or other isoforms requires careful validation. Overall, GYS1 antibodies are vital for advancing research in glycogen metabolism, metabolic diseases, and oncology.
×
